

### Company Overview

BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes artificial intelligence to identify improved therapies in neuroscience and immuno-oncology. BTI's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. BTI's two most advanced clinical development programs are BXCL501, an investigational, proprietary, orally dissolving thin film formulation of dexmedetomidine for the treatment of agitation and opioid withdrawal symptoms, and BXCL701, an investigational, orally administered, systemic innate immunity activator in development for the treatment of aggressive forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors.

### BioXcel Therapeutics Announces BXCL501 Met the Primary and All Secondary Endpoints in the TRANQUILITY Phase 1b/2 Study for the Acute Treatment of Agitation in Dementia, including Alzheimer's Disease

Jan 5 2021, 7:00 AM EST

### BioXcel Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference

Dec 17 2020, 7:00 AM EST

### BioXcel Therapeutics Announces Grant by U.S. Department of Defense to Evaluate BXCL501 in Patients Suffering from PTSD

Dec 7 2020, 7:00 AM EST

### Stock Overview

Symbol	BTAI	Solebury Trout
Exchange	Nasdaq	John Graziano
Market Cap	1.25b	T: 1.646.378.2942
Last Price	\$51.37	<a href="mailto:jgraziano@troutgroup.com">jgraziano@troutgroup.com</a>
52-Week	\$13.78 - \$71.50	

01/26/2021 04:00 PM EST

### Investor Relations

### Management Team

#### Vimal Mehta, Ph.D.

Chief Executive Officer & Founder

#### Frank D. Yocca, Ph.D.

Chief Scientific Officer

#### Vincent J.O'Neill M.D.

Senior Vice President & Chief Medical Officer

#### Reina Benabou, M.D., Ph.D.

Senior Vice President & Chief Development Officer

#### Chetan Lathia Ph.D.

Senior Vice President and Head of Translational Medicine, Clinical Pharmacology and Regulatory Affairs

#### Richard I. Steinhart

Chief Financial Officer & Vice President

#### William P. Kane

Chief Commercial Officer

### BioXcel Therapeutics, Inc.

555 Long Wharf Drive  
12th Floor  
New Haven, CT 06511  
United States

### Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.